Optomed Q4: Solid basis for growth
Redeye maintains the base case of EUR 7. 7 per share for Optomed after the Q4 report today. Despite the temporary revenue setback due to the covid-19 crisis making traditional sales models inefficient, we believe the company has laid down important building blocks for future growth. We expect results to be seen during 2021 and beyond.